Please assess the completion status of the following clinical trial:

Trial Title: Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* On thrice weekly chronic hemodialysis for at least 6 months~* Clinically stable, adequately dialyzed \[single-pool Kt/V \> 1.2 or Urea Reduction Ratio (URR) \> 65%\] thrice weekly, with polysulphone membrane for at least 3 consecutive months prior to study~Exclusion Criteria:~* History of functional transplant less than 6 months prior to study~* Use of immunosuppressive drugs within 1 month prior to study~* History of active connective tissue disease~* History of acute infectious disease within one month prior to study~* AIDS (HIV seropositivity is not an exclusion criteria)~* History of myocardial infarction or cerebrovascular event within 3 months~* Advanced liver disease~* Gastrointestinal dysfunction requiring parental nutrition~* Active malignancy excluding basal cell carcinoma of the skin~* History of ACE inhibitor-associated cough (intolerable) or angioedema~* Ejection fraction less than 30%~* Inability to discontinue ACE inhibitor or ARB~* Predialysis potassium repeatedly higher than 6.0 mmol/L (confirmed on a repeated blood draw)~* Anticipated live donor kidney transplant~* Pregnancy or breast-feeding~* History of poor adherence to hemodialysis or medical regimen~* Inability to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Valsartan (Type: ACTIVE_COMPARATOR): 80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
- Ramipril (Type: ACTIVE_COMPARATOR): 2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 5 mg of ramipril taken orally on a daily basis for 18 months
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).